

Sativa Investments

07:56 12 Oct 2018

Medical cannabis to be available in UK on prescription by start of November

Medicinal cannabis products, used in the treatment of various conditions that cause chronic pain, will be available on prescription to patients from the start of next month following a rescheduling of the drug by UK Home Secretary Sajid Javid.

People suffering from chronic pain, epilepsy, or nausea as a result of chemotherapy or multiple sclerosis (MS) will be among the first to be prescribed the drugs, which marks a turning point in the push to legalise cannabis products in the UK.

READ: Medicinal cannabis investor Sativa Investments reports 'significant progress' post IPO

At the moment, cannabis-derived can only be prescribed in exceptional circumstances after permission is granted by a panel of medical experts, although the Home Office will relax the rules from 1 November.

The policy change follows an incident in June when 12-year old Billy Caldwell had his cannabis oil, prescribed to alleviate the symptoms of epilepsy, confiscated at Heathrow Airport, a decision that was only reversed when an emergency permit was issued by the government.

However, Jeremy Thomas, chief executive and founder of medical cannabis company Sativa Investments PLC (NEX:SATI) said last week that the move by the government is not an indicator that the legalisation of recreational marijuana is in the offing.

Instead, Thomas says things will "become clearer" regarding the details of how the medical cannabis industry in the UK will take shape.

He adds that existing manufacturers outside the UK will likely be awarded limited export licenses for medical cannabis products, with investors "becoming more aware" of the scale of the industry.

"[Investors] will recognise that we [the UK] will be a very significant cannabis market," he says.

Price: 6.75p

Market Cap: £0M

1 Year Share Price Graph



May 2018 November 2018 May 2019

Share Information

Code: SATI

Listing: NEX

Sector: Health Care, Equipment & Services

Website: sativainvestments.co.uk

Company Synopsis:

Sativa seeks to invest in companies which are well-placed to take advantage of the dynamic regulatory environment surrounding medical Cannabis. Our investment strategy focuses on production, pharmacology, testing and compliance, R&D commercialisation, and sales and marketing. The Directors are already engaging with possible target investments in their key areas of interest.

Author:

Proactive Investors Ltd

+44 (0)207 989 0813

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content

published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.